Table 2 Efficacy of TUNA. Non-comparative studies

Symptom index

Studies

14^{26,28–30,32,33,35,36,38,43,45–48}

14^{25,26,28–30,32,33,35,36,38,39,41,43,45}

13^{30,32–36,38,39,41,43–45, 47}

4^32,36,43,44

2^42,44

1⁴⁴

2^44,49

No. patients

650

661

868

403

297

206

394

Effect

-11.33

-12.52

-12.59

-12.98

-9.94

-10.2

-10.99

95% CI

-14.1,-8.6

-15, -9.9

-14, -11.4

-14.2,- 11.8

-10, -9

-11,-9.

-14,- 8.3

P-value

.000

.000

.000

.000

.000

.000

.000

%improvement

53%

59%

59%

61%

47%

48%

51%

Quality-of-life score

Studies

12^{26,28,30,32,33,35,36,38,43,45,47,48}

13^{25,26,28,30,32,33,35,36,38,39,41,43,45}

14^{30,32–36,38,39,41,43–47}

5^{32,36,43,44,46}

1⁴⁴

1⁴⁴

2^44,49

No. patients

545

646

959

496

206

206

394

Effect

-2.80

-2.79

-2.60

-2.51

-2.1

-1.9

-2.14

95% CI

-3.3, -2.3

-3.2,-2.4

-3, -2.15

-2.8, -2.23

‡

‡

-3.2, -1.

P-value

.000

.000

.000

.000

‡

‡

.000

%improvement

60%

60%

56%

54%

45%

41%

46%

Qmax (mL/s)

Studies

15^{25,26,28–30,33,35–38,43,45–48}

17^{25,26,28–30,32–39,41,43,45,46}

14^{30,32–36,38,39,41,43–47}

4^32,36,43,44

2^42,44

1⁴⁴

2^44,49

No. patients

578

817

960

403

297

206

394

Effect

5.381

5.32

4.40

5.029

3.48

4.10

3.53

95% CI

3.67,7.08

3.7, 6.9

2.94, 5.86

4.35, 5.7

1.5, 5.4

3.2, 4.9

2.9, 4.2

P-value

.000

.000

.000

.000

.001

.000

.000

%improvement

33%

34%

45%

37%

57%

49%

56%

PVR (mL)

Studies

11^{28,29,33,35–38,43,45,47,48}

10^{28,29,33,35,36,38,39,43,45,46}

10^{33–36,38,39,43,45,47}

2^45,52

NA

NA

1⁴⁹

No. patients

440

557

598

77

188

Effect

-29.55

-37.6

-32.10

-29.5

-58

95% CI

-38.9, -20

-49.7,-25.5

-44,-20

-47.5,- 11.5

-76,-40

P-value

.000

.000

.000

.001

.000

%improvement

28%

36%

31%

28%

56%

P _det at Qmax (cm H ₂ O)

Studies

3^32,35,36

7^{26,29,30,32,35–37}

2^32,36

2^32,36

NA

NA

NA

No. patients

238

247

167

167

Effect

-24.64

-25.36

-22.74

-24.48

95% CI

-35.6,-13.6

-33.2,-17.5

-29.5, -16

-40, -8.92

P-value

.000

.000

.000

.002

%improvement

28%

29%

25%

28%

Prostatic size

Studies

7^{26,28,31,33,35,43,48}

5^{29,33,41,43,46}

4^30,33,43,46

1⁴³

NA

NA

1⁴⁹

No. patients

242

257

140

8

131

Effect

-6.32

-6.45

-7.89

-7.9

1.9

95% CI

-9.1,-3.5

-9.6,-3.3

-10.6,-5.1

-17.7,1.9

-3.4,7.2

P-value

.00

.00

.00

.11

.48

% reduction

14%

14%

17%

17%

0%